Epithalon side effects by evidence tier: what the Russian human series and the lifelong mouse study recorded, what that tier cannot show, the telomerase question and purity as a confound.
Epithalon — the pineal tetrapeptide Ala-Glu-Asp-Gly, also spelled epitalon — has a reputation for being "side-effect free". That phrase describes the shape of the evidence more than the safety of the molecule: the studies that exist did not report adverse effects, and the studies that could have found them were never run. It is a research reference beside the Epithalon profile, not advice.
Almost the entire epithalon record comes from one institute — Vladimir Khavinson's group at what is now the St Petersburg Institute of Bioregulation and Gerontology — and most of it was published in Russian. The layers are: cell-culture studies of telomerase, rodent and primate studies of ageing markers, and a handful of small human studies, only one of them placebo-controlled and none registered on ClinicalTrials.gov. The Epithalon research overview covers what those layers claim about efficacy; this page is only about tolerability.
That evidence tier can show one thing well: whether an obvious, acute toxicity appears at the amounts given. It cannot show incidence of common side effects, because uncontrolled series have no placebo arm to subtract background symptoms from. It cannot show rare events, because the cohorts were dozens of people, not thousands. And it cannot show long-term effects, because no human follow-up of the tetrapeptide beyond a course of weeks has been published.
The human studies of the tetrapeptide itself used three routes. Ten-day intramuscular courses were given to older adults in the institute's geriatric work; an unblinded study in retinitis pigmentosa administered epithalon by parabulbar injection beside the eye; and a small placebo-controlled study gave a sublingual formulation to older adults and measured melatonin output. Across these, the investigators reported no adverse effects attributable to the peptide.
It is equally worth stating what the reports lack: a systematic adverse-event schedule, a denominator, a comparator in all but one study, and English-language primary data. The Khavinson and Morozov mortality study most often cited for epithalon's human safety — 266 older adults followed six to eight years, published in Neuro Endocrinology Letters in 2003 — administered epithalamin and thymalin, the bovine pineal and thymic extracts. It contains no data on the synthetic tetrapeptide. The Epithalon dosage notes set out how each of the human studies administered the peptide.
Anisimov and colleagues' lifelong study, published in Biogerontology in 2003, gave female SHR mice 1 µg of epithalon subcutaneously on five consecutive days each month from three months of age until natural death. The authors reported no toxicity and no shortening of life. Mean lifespan was unchanged; the last 10% of survivors lived 13.3% longer and maximum lifespan rose 12.3%. Chromosome aberrations in bone-marrow cells fell. Total spontaneous tumour incidence did not change, while leukaemia incidence was roughly six-fold lower in treated animals.
Studies in aged rats and monkeys reported restored melatonin and cortisol rhythms, again without adverse effects. Two caveats apply. First, mouse doses in micrograms per animal cannot be scaled to humans by body weight and read as a safety margin; no pharmacokinetic study of epithalon exists in any species, so there is no exposure metric to compare. Second, monthly five-day courses in mice are a different exposure from the milligram-per-day schedules that circulate online, for which there is no animal data either.
Epithalon's defining finding is that it induces telomerase expression and lengthens telomeres in cultured human cells — first reported by Khavinson, Bondarev and Butyugov in the Bulletin of Experimental Biology and Medicine in 2003 and reproduced in 2025 by an unaffiliated group at Brunel University London in Biogerontology. Telomerase is also the enzyme most human cancers reactivate to keep dividing, which is where the theoretical concern comes from: what helps normal cells past their replicative limit could in principle help abnormal cells too.
The 2025 replication added a specific data point. In two breast-cancer cell lines, epithalon lengthened telomeres not through telomerase but through the alternative ALT pathway. That is a cell-culture observation, not an outcome, but it is a reason for caution rather than reassurance; the mouse study's unchanged tumour incidence points the other way. Neither has been tested in a human. "No signal found" and "looked for and not found" are different statements, and only the first applies here.
Community and vendor sources describe epithalon as unremarkable to use, with occasional injection-site redness, vivid dreams or altered sleep timing in the first days, and transient headache. These are uncontrolled self-reports with no denominator and no verification of what was in the vial; they cannot establish incidence or causation.
For a molecule this small, the vial matters as much as the sequence. At roughly 390 Da, the acetate counter-ion and residual water can be a meaningful fraction of the gross weight, so net peptide content on the certificate of analysis is worth reading alongside HPLC purity. A reaction in unregulated use may trace to synthesis impurities, residual solvents or endotoxin rather than to the tetrapeptide, and independent testing is the only way to tell — see lab testing and COAs and the cold-chain and shelf-life guide. The 10 mg epithalon vial sold here is third-party HPLC tested by lot.
Epithalon has no Health Canada market authorisation and no Drug Identification Number; it is not an ingredient in any authorised drug or natural health product, and research-grade material is sold in Canada for laboratory use only. In September 2023 the U.S. FDA placed epitalon in category 2 of its section 503A bulk-substance evaluation, citing the absence of adequate safety data, which bars it from compounded medicines there. Epithalon is not named on the WADA Prohibited List, but as a substance with no approval from any regulator it falls within S0, non-approved substances, and tested athletes should treat it as prohibited.
Does epithalon have a documented side-effect profile? No. The Russian human studies and the lifelong mouse study reported no adverse effects at the amounts given, but no blinded trial has recorded adverse events systematically, and no long-term human follow-up of the tetrapeptide exists.
Is the 266-person mortality study evidence of epithalon's safety? It is not evidence about epithalon at all. Khavinson and Morozov's 2003 study administered epithalamin and thymalin, the pineal and thymic extracts, not the synthetic tetrapeptide sold as epithalon.
Is the cancer concern real? It is theoretical and untested. Epithalon induces telomerase in normal cultured cells, and the 2025 Brunel study found ALT-pathway telomere lengthening in breast-cancer lines; the mouse study found no rise in total tumours and fewer leukaemias. No human study has been designed to answer the question.
What did the mouse lifespan study report about toxicity? Anisimov et al. (2003) gave 1 µg per mouse subcutaneously for five days each month for life and reported no toxicity, unchanged mean lifespan, a 12.3% rise in maximum lifespan and unchanged total tumour incidence.
Can animal doses be converted to a human safety margin? No. There is no pharmacokinetic study of epithalon in any species, so there is no exposure measure to scale.
Is this medical advice? No. This page summarises published research for laboratory reference. It is not medical advice, not a safety assurance, and not a dosing recommendation. Epithalon is sold here for research use only.
